SCHEMBL6679671

SCHEMBL6679671

CN1CC(C(=O)OCc2ccc(F)cc2)=Cc2c1[nH]c(=O)n(Cc1ccccc1)c2=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MMP12 P39900 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
GAA P10253 2/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
MAPT P10636 3/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 2/20 0.38
LMNA P02545 2/20 0.38
USP2 O75604 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
MAPK10 P53779 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RECQL P46063 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
GFER P55789 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6678658 0.90 KDM4E (0.39) MMP1MMP2MMP9MMP12RXFP1
SCHEMBL6683557 0.84 MMP1 (0.47) MMP1MMP2MMP9MMP12GAA
SCHEMBL6664325 0.83 TRPA1 (0.46) RXFP1L3MBTL1MAPTALDH1A1KDM4E
SCHEMBL6678347 0.81 ALDH1A1 (0.43) ALDH1A1KDM4ELMNAUSP2HPGD
SCHEMBL7131191 0.81 MMP1 (0.40) MMP1MMP2MMP9MMP12RXFP1
SCHEMBL7123023 0.76 L3MBTL1 (0.42) L3MBTL1ALDH1A1LMNANPSR1SMN1; SMN2
SCHEMBL6683778 0.75 PARP1 (0.39) L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL6683369 0.74 KLKB1 (0.41) RXFP1KDM4ELMNAHTT
SCHEMBL6683636 0.72 PARP1 (0.34) SMN1; SMN2
SCHEMBL6695961 0.72 MMP1 (0.36) MMP1MMP2MMP9MMP12GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 MMP1 7/4885MMP2 16/4885MMP9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.